全国性分析:开放与微创胸腺切除术治疗I-III期胸腺癌的比较
基于美国国家癌症数据库2010至2015年216例Masaoka I-III期胸腺癌胸腺切除术的分析,其中43例(20%)为微创手术(22例电视辅助胸腔镜、21例机器人)。倾向性评分匹配后,微创组与开放组在住院时间、30天再入院、30天和90天死亡率、切缘阳性及5年生存率上均无显著差异。
要点
- 微创胸腺切除术占本组胸腺癌手术的20%(43/216),包括电视辅助胸腔镜和机器人两种方式。
- 倾向性评分匹配后,微创组与开放组的中位住院时间、30天再入院率、30天和90天死亡率及切缘阳性率均无显著差异。
- 匹配后5年生存率微创组78.6% vs 开放组54.6%,差异未达统计学显著(P=0.15)。
核心结论
- 在这项全国性分析中,微创胸腺切除术治疗I-III期胸腺癌与开放胸腺切除术相比,短期结局和总生存均无显著差异。
研究设计与样本
- 采用倾向性评分匹配分析和多因素Cox比例风险模型评估围手术期结局与总生存,并按意向性治疗分析评估不同手术方式的结果。
主要发现
- 全队列中,微创组中位住院时间较开放组缩短(3天 vs 5天,P < 0.001)。
- 倾向性评分匹配30例开放与30例微创胸腺切除术后,微创组与开放组的中位住院时间无显著差异(3天 vs 4.5天,P = 0.27)。
- 匹配后,微创组与开放组的30天再入院(P = 0.13)、30天死亡率(P = 0.60)、90天死亡率(P = 0.60)、切缘阳性(P = 0.39)均无显著差异。
- 匹配后,微创组与开放组的5年生存率分别为78.6%与54.6%,差异未达统计学显著(P = 0.15)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The oncological efficacy of minimally invasive thymectomy for thymic carcinoma is not well characterized. We compared overall survival and short-term outcomes between open and minimally invasive surgical (video-assisted thoracoscopic and robotic) approaches using the National Cancer Database. METHODS: Perioperative outcomes and overall survival of patients who underwent open versus minimally invasive thymectomy for Masaoka stage I-III thymic carcinoma from 2010 to 2015 in the National Cancer Database were evaluated using propensity score-matched analysis and multivariable Cox proportional hazards modelling. Outcomes by surgical approach were assessed using an intent-to-treat analysis. RESULTS: Of the 216 thymectomies that were evaluated, 43 (20%) were performed with minimally invasive techniques (22 video-assisted thoracoscopic and 21 robotic). The minimally invasive approach was associated with a shorter median length of stay when compared to the open approach (3 vs 5 days, P < 0.001). In the propensity score-matched analysis of 30 open and 30 minimally invasive thymectomies, the minimally invasive group did not differ significantly in median length of stay (3 vs 4.5 days, P = 0.27), 30-day readmission (P = 0.13), 30-day mortality (P = 0.60), 90-day mortality (P = 0.60), margin positivity (P = 0.39) and 5-year survival (78.6% vs 54.6%, P = 0.15) when compared to the open group. CONCLUSIONS: In this national analysis, minimally invasive thymectomy for stage I-III thymic carcinoma was found to have no significant differences in short-term outcomes and overall survival when compared to open thymectomy.
引用
- Hurd J, Haridas C, Potter A, et al. A national analysis of open versus minimally invasive thymectomy for stage I-III thymic carcinoma. Eur J Cardiothorac Surg. 2022. PMID: 35259241. doi:10.1093/ejcts/ezac159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。